Amy Damask

Title: Amy Damask: Innovator in Sepsis and Cardiovascular Risk Treatment

Introduction

Amy Damask is a prominent inventor based in Tarrytown, NY (US). She has made significant contributions to the fields of medicine and biotechnology, particularly in the treatment of sepsis and cardiovascular risk. With a total of two patents to her name, her work is paving the way for innovative therapeutic approaches.

Latest Patents

Amy Damask's latest patents include groundbreaking methods for treating sepsis with PCSK9 and LDLR modulators. This patent provides methods for treating subjects with sepsis, SIRS, septic shock, and/or MODS. It also outlines methods for identifying subjects at increased risk of developing these conditions and detecting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) variant nucleic acid molecules and polypeptides. Additionally, she holds a patent for genome-based methods aimed at reducing cardiovascular risk through the administration of a PCSK9 inhibitor to patients with a genetic profile that responds to this therapy.

Career Highlights

Amy Damask is currently employed at Regeneron Pharmaceuticals, Inc., where she continues to advance her research and innovations. Her work is instrumental in developing new treatments that can significantly improve patient outcomes in critical health conditions.

Collaborations

Throughout her career, Amy has collaborated with notable colleagues, including Charles Paulding and Aris I Baras. These partnerships have enhanced her research efforts and contributed to the success of her innovative projects.

Conclusion

Amy Damask is a trailblazer in the medical field, with her patents reflecting her commitment to improving health outcomes for patients suffering from sepsis and cardiovascular issues. Her work at Regeneron Pharmaceuticals, Inc. continues to inspire advancements in medical treatments.